The New York denial segment captures a specific configuration: the member holds a fully-insured NY-licensed plan issued in New York — Empire BlueCross BlueShield, UnitedHealthcare/Oxford Health, Aetna, Cigna, Excellus, MVP Health Care, CDPHP, EmblemHealth, Fidelis Care, Healthfirst, Independent Health, MetroPlusHealth, and the like — and has received an Adverse Benefit Determination, or after exhausting the carrier’s internal appeal, a Final Adverse Determination on the EOB. The denial reason will track the carrier’s internal reason code (medical necessity, prior authorization, step therapy, formulary exclusion, out-of-network), but the appeal frameworks that attach are New York-specific. The New York State Department of Financial Services (NYDFS) regulates fully-insured NY plans under Insurance Law Article 32 (N.Y. Ins. Law § 3201 et seq.), with § 4914 spelling out the external appeal pathway — 4-month filing window from the Final Adverse Determination, an Approved Review Organization (ARO) review where the ARO’s decision is binding on the carrier, overseen by NYDFS — and § 4905 supplying the 24-hour expedited external appeal channel for ongoing care. The NYDFS Consumer Hotline is the front door for NY members — 1-800-342-3736, dfs.ny.gov.
NY-licensed carriers operating in New York — Empire BlueCross BlueShield (Elevance), UnitedHealthcare/Oxford Health, Aetna, Cigna, the NY-domestic carriers — are subject to the N.Y. Ins. Law § 3214-a framework for first-level internal appeals, the § 4914 external appeal pathway with a 4-month filing window from the Final Adverse Determination, the 11 NYCRR 71.4 binding ARO procedure (the ARO list is published and maintained by NYDFS), and the 24-hour NYDFS expedited external appeal response under § 4905 — a parallel channel to the federal 72-hour urgent-claim framing in ERISA § 503 for self-funded employer plans. 11 NYCRR 410.5 supplies the carrier’s obligation to disclose the clinical criteria and guidelines used in the Adverse Benefit Determination on request. The § 4914 external appeal runs in parallel with the federal 4-month ACA external review window at 45 C.F.R. § 147.136(d) for ACA marketplace plans operating in New York, and the NY-specific binding ARO decision wins where both attach.
Self-funded ERISA plans — the typical larger-employer group plan where the employer pays the claims rather than buying insurance from a carrier — fall outside NYDFS regulation and outside 11 NYCRR 71.4, and run through the federal ERISA § 503 claims-procedure rule at 29 C.F.R. § 2560.503-1, with the 4-month federal external-review channel at 29 C.F.R. § 2590.715-2719 for non-grandfathered plans and ERISA § 502(a) civil action at 29 U.S.C. § 1132(a)(1)(B) as the post-exhaustion remedy. NY UR laws (11 NYCRR 410.5 et seq.) still apply to procedural aspects the federal rule does not preempt — clinical-criteria disclosure, peer-reviewer escalation, the UR agent standards — but the appeals timeline and the right-to-file-a-civil-action follow fully from 29 C.F.R. § 2560.503-1 and ERISA § 502(a). A well-built New York appeal letter cites both: the controlling NY statute (N.Y. Ins. Law § 4914 / 11 NYCRR 71.4 for fully-insured NY plans) or the federal preemption fallback (29 C.F.R. § 2560.503-1 for self-funded ERISA), and the right federal framework underneath.